<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598036</url>
  </required_header>
  <id_info>
    <org_study_id>AUR-VCS-2017-03</org_study_id>
    <nct_id>NCT03598036</nct_id>
  </id_info>
  <brief_title>Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis</brief_title>
  <acronym>AURONA™</acronym>
  <official_title>An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission
      of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the current study to assess the efficacy of voclosporin in achieving complete or
      partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental
      glomerulosclerosis (FSGS). As well as to assess the safety and tolerability of voclosporin
      over 24 weeks in subjects with FSGS.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment rate
  </why_stopped>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Actual">May 19, 2020</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with remission of proteinuria</measure>
    <time_frame>24 weeks</time_frame>
    <description>Complete remission OR Partial remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with complete remission or partial remission of proteinuria</measure>
    <time_frame>Weeks 8 and 12</time_frame>
    <description>Complete remission or partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with complete remission of proteinuria</measure>
    <time_frame>Weeks 8, 12, and 24</time_frame>
    <description>Complete remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with reduction of proteinuria</measure>
    <time_frame>Weeks 8, 12, and 24</time_frame>
    <description>Reduction of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with partial remission of proteinuria</measure>
    <time_frame>Weeks 8, 12, and 24</time_frame>
    <description>Partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of complete or partial remission of proteinuria</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Complete OR partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of complete remission of proteinuria</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Complete remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of partial remission of proteinuria</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Partial remission of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of 50% reduction in UPCR from baseline</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>50% reduction in UPCR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of reduced UPCR</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Duration of reduced UPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in UPCR</measure>
    <time_frame>Week, 2,4,8,12,18,24</time_frame>
    <description>Change from baseline in UPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a confirmed decrease from baseline in eGFR</measure>
    <time_frame>Week, 2,4,8,12,18,24</time_frame>
    <description>Utilizing the CKD-EPI formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a confirmed increase in eGFR</measure>
    <time_frame>Final Visit (week 24) to second Safety Follow-up visit (Visit 10)</time_frame>
    <description>Increase in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UPCR</measure>
    <time_frame>Week 24 and 26</time_frame>
    <description>Change in UPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>Week 24 and 26</time_frame>
    <description>Change in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum creatinine, serum albumin, and eGFR</measure>
    <time_frame>Week, 2,4,8,12,18,24</time_frame>
    <description>Change from baseline in serum creatinine, serum albumin, and eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>Week 24</time_frame>
    <description>Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (treatment-emergent adverse events)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence and number of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal biopsy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1:
Maximum dose of 3 capsules (7.9mg) BID
Cohort 2
Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voclosporin</intervention_name>
    <description>Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).
The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1.</description>
    <arm_group_label>Voclosporin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary FSGS diagnosed by renal biopsy.

          2. Urine protein creatinine ratio (UPCR) ≥2.0 mg/mg, serum albumin ≤3.2 g/dL and can be
             immunosuppressant treatment-naïve, or receiving treatment with steroids.

          3. Stable proteinuria, renal function, and BP.

        Exclusion Criteria:

          1. Clinical or histologic evidence of secondary FSGS.

          2. Histologic evidence of collapsing variant FSGS.

          3. eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
             equation of ≤30 mL/minute/1.73 m2 at initial screening assessment or ≤45
             mL/minute/1.73 m2 at last qualifying assessment.

          4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected
             to require dialysis during the study period.

          5. Current or medical history of:

               -  Congenital or acquired immunodeficiency.

               -  In the opinion of the Investigator, clinically significant drug or alcohol abuse
                  within 2 years prior to screening.

               -  Malignancy within 5 years of screening, with the exception of basal and squamous
                  cell carcinomas treated by complete excision.

               -  Current or past lymphoproliferative disease or previous total lymphoid
                  irradiation.

               -  Severe viral infection within 3 months of screening, or known HIV infection.
                  Severe viral infection is defined as active disease requiring antiviral therapy.

               -  Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking
                  prophylaxis with isoniazid.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Centre</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Centre</name>
      <address>
        <city>Santiago De Los Caballeros</city>
        <zip>51000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSGS Investigative Center</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309.</citation>
    <PMID>24330024</PMID>
  </reference>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8.</citation>
    <PMID>23996158</PMID>
  </reference>
  <reference>
    <citation>Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4.</citation>
    <PMID>23736966</PMID>
  </reference>
  <reference>
    <citation>Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22.</citation>
    <PMID>21943027</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calcineurin inhibitors</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

